MedTrace Logo

Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia

NCT02813694 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 738

Last updated 2019-10-23

Study results available
· View outcomes & findings →

Summary

This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate community-acquired bacterial pneumonia

Conditions

  • Community Acquired Pneumonia

Interventions

DRUG

lefamulin

antibacterial agent

DRUG

Moxifloxacin

antibacterial agent

Sponsors & Collaborators

  • Nabriva Therapeutics AG

    lead INDUSTRY

Principal Investigators

  • Leanne Gasink, MD · Nabriva Therapeutics AG

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • United States
  • Argentina
  • Brazil
  • Bulgaria
  • Chile
  • Georgia
  • Hungary
  • Latvia
  • Mexico
  • Peru
  • Philippines
  • Poland
  • Romania
  • Russia
  • Serbia
  • South Africa
  • South Korea
  • Spain
  • Taiwan
  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02813694 on ClinicalTrials.gov